Quanterix Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Quanterix in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Quanterix stock.
View analyst ratings for Quanterix or view top-rated stocks.

Wall Street analysts have given Quanterix a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Quanterix wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Quanterix is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Quanterix.

Quanterix Co. (NASDAQ:QTRX) released its quarterly earnings data on Monday, March, 1st. The company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.02. Quanterix had a negative trailing twelve-month return on equity of 22.37% and a negative net margin of 41.69%.
View Quanterix's earnings history.

Quanterix's stock was trading at $18.51 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, QTRX shares have increased by 264.0% and is now trading at $67.37.
View which stocks have been most impacted by COVID-19.

Quanterix issued an update on its fourth quarter 2020 IntraDay earnings guidance on Wednesday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $20-22 million, compared to the consensus revenue estimate of $21.7 million.

3 equities research analysts have issued 1 year target prices for Quanterix's shares. Their forecasts range from $40.00 to $90.00. On average, they expect Quanterix's share price to reach $71.67 in the next year. This suggests a possible upside of 6.4% from the stock's current price.
View analysts' price targets for Quanterix or view top-rated stocks among Wall Street analysts.

15 employees have rated Quanterix CEO Kevin Hrusovsky on Glassdoor.com. Kevin Hrusovsky has an approval rating of 70% among Quanterix's employees.

Some companies that are related to Quanterix include Bruker (BRKR), Coherent (COHR), Pacific Biosciences of California (PACB), Berkeley Lights (BLI), Bionano Genomics (BNGO), Accelerate Diagnostics (AXDX), Fluidigm (FLDM), EyePoint Pharmaceuticals (EYPT), Harvard Bioscience (HBIO), Precipio (PRPO), Astrotech (ASTC), HTG Molecular Diagnostics (HTGM), Scientific Industries (SCND), BioForce Nanosciences (BFNH) and Pressure BioSciences (PBIO).
View all of QTRX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Quanterix investors own include Editas Medicine (EDIT), Novavax (NVAX), Akoustis Technologies (AKTS), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), The Walt Disney (DIS), Illumina (ILMN), Sorrento Therapeutics (SRNE), Cisco Systems (CSCO) and Intellia Therapeutics (NTLA).

(QTRX) raised $50 million in an initial public offering (IPO) on Thursday, December 7th 2017. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morga and Leerink Partners served as the underwriters for the IPO and BTIG and Evercore ISI were co-managers.

Quanterix trades on the NASDAQ under the ticker symbol "QTRX."

Quanterix's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.50%), Frontier Capital Management Co. LLC (4.74%), Price T Rowe Associates Inc. MD (3.58%), Ashford Capital Management Inc. (1.30%), Tikvah Management LLC (1.21%) and Monashee Investment Management LLC (1.26%). Company insiders that own Quanterix stock include Amol Chaubal, David C Duffy, David R Walt, Dawn Mattoon, E Kevin Hrusovsky, John J Fry, Marijn E Dekkers, Mark T Roskey and Martin D Madaus.
View institutional ownership trends for Quanterix.

QTRX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Price T Rowe Associates Inc. MD, Nuveen Asset Management LLC, Next Century Growth Investors LLC, Royce & Associates LP, Assenagon Asset Management S.A., Northern Trust Corp, and Bank of New York Mellon Corp. Company insiders that have sold Quanterix company stock in the last year include Amol Chaubal, David C Duffy, Dawn Mattoon, E Kevin Hrusovsky, John J Fry, Marijn E Dekkers, Mark T Roskey, and Martin D Madaus.
View insider buying and selling activity for Quanterix or view top insider-selling stocks.

QTRX stock was bought by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Clearbridge Investments LLC, Monashee Investment Management LLC, Caas Capital Management LP, Laurion Capital Management LP, First Trust Advisors LP, Lord Abbett & CO. LLC, and ExodusPoint Capital Management LP.
View insider buying and selling activity for Quanterix or or view top insider-buying stocks.

Shares of QTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of QTRX stock can currently be purchased for approximately $67.37.

Quanterix has a market capitalization of $2.42 billion and generates $56.73 million in revenue each year. The company earns $-40,800,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis.

Quanterix employs 248 workers across the globe.

The official website for Quanterix is www.quanterix.com.

Quanterix is headquartered at 900 MIDDLESEX TURNPIKE, BILLERICA MA, 01821.

Quanterix's mailing address is 900 MIDDLESEX TURNPIKE, BILLERICA MA, 01821. The company can be reached via phone at 617-301-9400 or via email at [email protected]